Panelists discuss how they approach selecting among various immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor ...

Saeed Sadeghi, MD, discusses the updated data from the COMMANDS study presented at ASCO 2024, emphasizing the significance of ...

Joshua K. Sabari, MD, discusses how tarlatamab, a BiTE, demonstrates a unique mechanism of action by targeting DLL3, which is ...

Joshua K. Sabari, MD, discusses how, despite negative results from serial brain MRIs, the consideration of PCI in patients with ES-SCLC depends on individual risk factors, including the likelihood of ...

The final analysis of the phase 3 PANTHER study confirmed survival benefits for patients receiving dose-dense vs standard ...

M. Michele Blackwood, MD, FACS, provided an overview of the significant advancements with personalized medicine with genomic ...

The noninvasive test provides a beneficial screening tool for patients 45 and older at average risk for colorectal cancer.

For Breast Cancer Awareness Month, Oranus Mohammadi, MD, discussed the remarkable progress made in improving survival rates ...

Robert Jotte, MD, PhD, discusses findings from the phase 3 KRYSTAL-12 study evaluating adagrasib in KRAS G12C-mutated NSCLC.

A new study found that adding daratumumab to lenalidomide, bortezomib, and dexamethasone significantly improved outcomes for ...

International Myeloma Society Annual Meeting was a groundbreaking event that showcased the latest advancements in multiple ...

In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow ...